Serial aminotransferase changes and perinatal outcomes in intrahepatic cholestasis of pregnancy
Öz
Purpose: The aim of this study was to evaluate serial aminotransferase changes and whether biochemical improvement differed according to neonatal intensive care unit admission in pregnancies complicated by intrahepatic cholestasis of pregnancy.
Materials and Methods: This retrospective cohort study included 59 women followed between February 2018 and August 2023. Maternal, obstetric, laboratory, delivery, and neonatal data were obtained from medical records. Alanine aminotransferase and aspartate aminotransferase measurements were recorded chronologically, although follow-up intervals were not standardized. First-to-last aminotransferase changes were evaluated, and maternal biochemical parameters were compared according to neonatal intensive care unit admission.
Results: Preterm delivery occurred in 33 pregnancies (55.9%), and 31 of these births (93.9%) were iatrogenic. Twenty-one newborns (35.6%) were admitted to the neonatal intensive care unit. Median alanine aminotransferase levels decreased from 88.0 [54.5–187.0] to 55.0 [17.5–125.0] U/L in 55 women, and median aspartate aminotransferase levels decreased from 70.0 [32.5–116.5] to 35.0 [22.0–46.5] U/L in 59 women. Alanine aminotransferase percentage change was 23.3% [-14.8 to 54.6] in newborns without neonatal intensive care unit admission and 37.9% [22.4 to 49.2] in those with admission. Aspartate aminotransferase percentage change was 27.2% [1.6 to 60.1] and 44.3% [20.8 to 60.8], respectively. Among the 39 women with available bile acid data, peak bile acid levels were 21.9 [10.7–55.2] µmol/L in the no-admission group and 22.7 [15.1–34.5] µmol/L in the admission group. Newborns admitted to the neonatal intensive care unit had lower gestational age at birth (35.4 [34.0–36.0] vs. 37.4 [36.0–38.1] weeks) and lower birth weight (2350.0 [2000.0–2730.0] vs. 2890.0 [2697.5–3267.5] g) than non-admitted newborns.
Conclusion: Serial aminotransferase improvement may be insufficient for neonatal risk stratification in intrahepatic cholestasis of pregnancy. Biochemical response should be interpreted together with obstetric and clinical risk indicators.
Anahtar Kelimeler
Cholestasis, Intrahepatic, Pregnancy complications, Alanine Aminotransferase, Aspartate Aminotransferases, Premature birth, intensive care units, neonatal
Destekleyen Kurum
This study received no financial or material support from any public institution, private company, or commercial organization.
Proje Numarası
Not applicable.
Etik Beyan
The study was approved by the Scientific Research Ethics Committee of Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital on September 20, 2023, with approval number 2023/164. The requirement for informed consent was waived by the ethics committee because of the retrospective design of the study and the use of anonymized medical record data. The study was conducted in accordance with the principles of the Declaration of Helsinki.
Teşekkür
None.
Kaynakça
- Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2014;124:120-33.
- Society for Maternal-Fetal Medicine (SMFM);Lee RH, Greenberg M, Metz TD, Pettker CM. Society for Maternal-Fetal Medicine Consult Series #53: Intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol. 2021;224:B2-9.
- Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019;393:899-909.
- Odabaş RK, Sökmen Y, Dünder E, Taşpınar A. The incidence of intrahepatic cholestasis of pregnancy and its maternal, fetal, and neonatal adverse outcomes: a systematic review and meta-analysis. J Midwifery Womens Health. 2024;69:370-82.
- Girling J, Knight CL, Chappell L;Royal College of Obstetricians and Gynaecologists. Intrahepatic cholestasis of pregnancy: Green-top Guideline No. 43. BJOG. 2022;129:e95-114.
- Hobson SR, Cohen ER, Gandhi S, Jain V, Niles KM, Roy-Lacroix MÈ et al. Guideline No. 452: diagnosis and management of intrahepatic cholestasis of pregnancy. J Obstet Gynaecol Can. 2024;46:102618.
- Chappell LC, Bell JL, Smith A, Linsell L, Juszczak E, Dixon PH et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy: a randomised controlled trial. Lancet. 2019;394:849-60.
- Çalık MG, Yücel Çelik Ö, Köksal Z, Yücel A. Assessment of perinatal outcomes in intrahepatic cholestasis of pregnancy in relation to transaminase and bile acid levels. BMC Pregnancy Childbirth. 2026;26:567.
- Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004;40:467-74.
- Geenes V, Chappell LC, Seed PT, Steer PJ, Knight M, Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology. 2014;59:1482-91.